By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Tobira Therapeutics Inc. 

214 Carnegie Center
Suite 306
Princeton  New Jersey  08540  U.S.A.
Phone: 609-897-1102 Fax: n/a


Company News
Tobira Announces Publication Of Phase 1 Study Results Showing Cenicriviroc Safety In Cirrhotic Patients 5/13/2016 7:37:30 AM
Tobira Reports First Quarter 2016 Financial And Business Results 5/10/2016 7:25:44 AM
Tobira Announces Interim 12-Week Results From The ORION Study 5/2/2016 7:40:13 AM
Tobira Announces Upcoming Presentations On Biomarkers For NASH At Two Scientific Meetings 4/22/2016 6:31:16 AM
Bay Area's Tobira Strikes a $74.5 Million Evogliptin and Cenicriviroc Deal with Dong-A ST 4/11/2016 6:35:42 AM
Tobira Therapeutics Inc. To Present At The 15th Annual Needham Healthcare Conference 4/5/2016 7:42:26 AM
Tobira Therapeutics Inc. Release: Independent Research To Be Presented At International Liver Congress Shows Cenicriviroc Improves Steatohepatitis And Liver Fibrosis In NASH Model 3/31/2016 10:33:24 AM
Tobira Therapeutics Inc. To Host Analyst And Investor Day On April 4, 2016 3/28/2016 7:19:44 AM
Tobira Therapeutics Inc. Announces Publication Of CENTAUR Phase 2b Study Design And Rationale In Contemporary Clinical Trials 3/9/2016 6:51:16 AM
Tobira Therapeutics Inc. Reports Fourth Quarter 2015 Financial And Year-End Business Results 3/4/2016 6:58:56 AM